GlassScriptPhysician profile
Julia Carroccio
NPI 1003565268
$1,343.13
in general payments reported to CMS, 2019-2025
26 companies · $1,343 in 2025
The $1,343 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,343.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $253.06 | 2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $157.90 | 2025 | Zepbound, Mounjaro |
| Abbvie INC. | $88.09 | 2025 | |
| Axsome Therapeutics, INC. | $85.19 | 2025 | Auvelity |
| Pfizer INC. | $83.38 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $80.02 | 2025 | Camzyos |
| Merck Sharp & Dohme LLC | $63.94 | 2025 | Verquvo, Enflonsia, Capvaxive |
| Exact Sciences Corporation | $52.75 | 2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $50.23 | 2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $39.86 | 2025 | Gvoke Hypopen, Recorlev |
| Harmony Biosciences LLC | $39.76 | 2025 | |
| Vanda Pharmaceuticals INC. | $35.58 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $31.18 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $30.92 | 2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $25.82 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25.73 | 2025 | Austedo Xr |
| Vertex Pharmaceuticals Incorporated | $23.61 | 2025 | |
| Antares Pharma, INC. | $23.31 | 2025 | Xyosted |
| Bausch Health US, LLC | $22.07 | 2025 | Aplenzin |
| Astellas Pharma US INC | $20.43 | 2025 | Veozah |
| Lundbeck LLC | $20.00 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.95 | 2025 | Caplyta |
| Dexcom, INC. | $19.70 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2025 | |
| Novo Nordisk INC | $16.89 | 2025 | Ozempic |
| Amgen INC. | $15.43 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Carroccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.